Intelligence · Patents
Patents expiring in 2032
Annual patent cliff calendar for 2032 — US pharmaceutical patents by expiration date.
- Patents
- 1,150
Quick answer
1,150 indexed pharmaceutical patents have expiration dates in 2032. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 8188132
Linked dibenzimidazole derivatives
granted -
US 8188095
Gyrase inhibitors and uses thereof
granted -
US 8188219
Bone morphogenic protein binding peptide
granted -
US 8188149
Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
granted -
US 8188214
Brachyury polypeptides and methods for use
granted -
US 8188259
Oligonucleotide-containing pharmacological compositions and their use
granted -
US 8188289
Conformationally restricted urea inhibitors of soluble epoxide hydrolase
granted -
US 8188221
Peptide homing to brain tumors
granted -
US 8188276
2,4-pyrimidinediamine compounds and their uses
granted -
US 8188283
Modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 8188294
Process for preparing biphenyl imidazole compounds
granted -
US 8188049
Peptides having activities of epidermal growth factor and its uses
granted -
US 8193352
Gyrase inhibitors and uses thereof
granted -
US 8193202
LIMK2 inhibitors, compositions comprising them, and methods of their use
granted -
US 8193145
Laminins, derivatives, and compositions including same and methods for their therapeutic use
granted -
US 8192741
Method of treating rheumatoid arthritis with an anti-IL-6R antibody
granted -
US 8193306
Methods for preparing polymeric reagents and compositions of polymeric reagents
granted -
US 8193204
Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1- (4-chloro-2-(3-methyl-1H-pyrazol-1-YL)phenyl)2,2,2-trifluoroethoxy)-pyrimidin-4-YL)phenyl)propanoate and methods of their use
granted -
US 8192991
Methods of eliciting or boosting a cellular immune response
granted -
US 8192720
Compositions and methods for detection, prevention, and treatment of anthrax and other infectious diseases
granted -
US 8193194
Ion channel modulators and methods of use
granted -
US 8193151
Methods for treating atrial or ventricular arrhythmias
granted -
US 8193181
Xinafoate salt of N4-(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy) phenyl]2,4-pyrimidinediamine
granted -
US 8193152
Treatment or prevention of hemorrhagic viral infections with immunomodulator compounds
granted -
US 8193211
Controlled release compositions of gamma-hydroxybutyrate
granted -
US 8193167
Pharmacologically active agents containing esterified phosphonates and methods for use thereof
granted -
US 8193312
Bone morphogenic protein binding peptide
granted -
US 8193330
Polynucleotides comprising Neurogenin3 promoter and bHLH encoding domains
granted -
US 8193357
Androgen receptor modulator compounds
granted -
US 8193197
Compositions and methods for inhibition of the JAK pathway
granted -
US 8193225
Isoxazole amides, derivatives and methods of chemical induction of neurogenesis
granted -
US 8193339
Synthesis of β-nucleosides
granted -
US 8193309
Compositions and methods for preventing or treating cancer
granted -
US 8197823
Vaccine for porcine reproductive and respiratory syndrome, a preparion method and use thereof
granted -
US 8198242
Variants of C-type natriuretic peptide
granted -
US 8198304
Guanidine-containing compounds useful as muscarinic receptor antagonists
granted -
US 8198402
Smoothened polypeptides and methods of use
granted -
US 8198255
SiRNA-mediated inhibition of doublecortin and Ca2+/calmodulin-dependent kinase-like-1
granted -
US 8198322
Apoptotic and anti-tumor activities of metallo-salens
granted -
US 8197818
EML4-ALK fusion gene
granted -
US 8197870
Depolymerization extraction of compounds from birch bark
granted -
US 8197838
Sustained release systems of ascorbic acid phosphate
granted -
US 8198042
CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection
granted -
US 8198469
Crystalline forms of tigecycline and processes for preparation thereof
granted -
US 8198244
Regulation of skin characteristics by DICKKOPF1 (DKK1)
granted -
US 8198254
Annexin A9 (ANXA9) biomarker and therapeutic target in epithelial cancer
granted -
US 8198406
Methods and compositions for inhibiting angiogenesis
granted -
US 8198470
Crystalline form II of tigecycline and processes for preparation thereof
granted
Frequently asked questions
How many pharma patents expire in 2032?
1,150 published patents in our USPTO index have expiration dates falling in calendar year 2032.